Gazyva (obinutuzumab)

P2, N=10, Not yet recruiting, Mario Negri Institute for Pharmacological Research

P1/2, N=40, Terminated, Pfizer | N=30 --> 40 | Active, not recruiting --> Terminated; Business/Administrative decision to pursue other programs/assets within the oncology portfolio. Not due to any detected safety signals or requests from regulatory authorities.

P1/2, N=940, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> Mar 2029 | Trial primary completion date: Dec 2029 --> Mar 2029

The patient achieved complete remission after six cycles of obinutuzumab, cyclophosphamide, vincristine, and prednisone. This case illustrates a rare presentation of nontranslocation follicular lymphoma mimicking infectious mononucleosis and emphasizes the importance of reconsidering hematologic malignancy in patients with persistent mucocutaneous inflammation and incongruent laboratory findings.

P1/2, N=25, Not yet recruiting, AstraZeneca AB

P3, N=100, Recruiting, Heidelberg University | Trial completion date: Dec 2029 --> Jun 2030 | Trial primary completion date: Dec 2026 --> Sep 2027

P2, N=37, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: Sep 2027 --> May 2028

P1/2, N=124, Completed, Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy | Recruiting --> Completed

P1/2, N=80, Recruiting, BeOne Medicines

P1, N=28, Not yet recruiting, Ruijin Hospital

Patients received cibisatamab with escalating doses of FAP-4-1BBL weekly or every 3 weeks after obinutuzumab pretreatment to mitigate anti-drug antibody formation. These findings demonstrate the feasibility of combining tumor antigen-directed T cell engagement with localized co-stimulation, with evidence of immune activation and preliminary antitumor activity supporting further clinical development. ClinicalTrials.gov identifier: NCT04826003 .

P2, N=89, Completed, Heidelberg University | Active, not recruiting --> Completed